Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
11 Marzo 2024 - 1:05PM
Business Wire
– Experienced Medical and Executive Leader, Dr.
Radhakrishnan served as Group SVP and Chief Medical Officer of
Biogen, responsible for the Worldwide Medical function –
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced
the appointment of Maha Radhakrishnan, M.D. to the company’s board
of directors. Dr. Radhakrishnan is an accomplished industry
executive with decades of experience advancing large strategic
portfolios across different therapeutic areas through product
development and commercialization and overseeing the global medical
strategy and operations within major biotechnology and
pharmaceutical companies.
“Maha joins our Board at a pivotal moment for Alto, as we
continue on our path and fulfill our ambition of redefining
psychiatry with our precision pipeline in areas of persistent
medical need,” said Amit Etkin, M.D., Ph.D., founder and chief
executive officer of Alto. “Throughout her distinguished career,
Maha has been dedicated to advancing patient care through more
personalized approaches to treatment. We believe her guidance and
input will be invaluable as we work to make precision psychiatry a
reality for patients, physicians, caregivers, and payers.”
Maha Radhakrishnan, M.D., recently served as group senior vice
president and chief medical officer of Biogen, responsible for the
worldwide medical function, until March 2024. Previously, Dr.
Radhakrishnan was senior vice president and global head of medical,
primary care business unit at Sanofi, a global biopharmaceutical
company focused on human health. At Sanofi, she led the function
providing the medical strategy for the diabetes and cardiovascular
products and programs in development. Prior, she held several
leadership roles at Bioverativ Inc., Bristol Myers Squibb, United
Health Group, and Cephalon. Dr. Radhakrishnan received her M.D. in
internal medicine with honors from the People’s Friendship
University in Moscow, Russia in 1995, as well as a master's degree
in Russian language.
“The emergence of precision psychiatry is critically important
given the urgent need to address the disparities in individual
responses across treatments in mental healthcare,” added Dr.
Radhakrishnan. “I am honored to join Alto’s board at such an
exciting time in the company’s journey and I am encouraged by the
data that has been exhibited across the company’s programs to date.
I believe successful stratification of patients can unlock the
ability to redefine psychiatric care in a truly meaningful way and
Alto’s Precision Psychiatry Platform has the potential to pioneer
this transformation.”
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company
with a mission to redefine psychiatry by leveraging neurobiology to
develop personalized and highly effective treatment options. Alto’s
Precision Psychiatry Platform™ measures brain biomarkers by
analyzing EEG activity, neurocognitive assessments, wearable data,
and other factors to better identify which patients are more likely
to respond to Alto product candidates. Alto’s clinical-stage
pipeline includes novel drug candidates in depression, PTSD,
schizophrenia, and other mental health conditions. For more
information, visit www.altoneuroscience.com or follow Alto on
X.
Forward Looking Statements
This press release may contain forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by words such as “aims,” “anticipates,” “believes,” “could,”
“estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,”
“plans,” “possible,” “potential,” “seeks,” “will” and variations of
these words or similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements regarding
Alto’s expectations concerning Dr. Radhakrishnan’s contributions to
its Board of Directors and other statements that are not historical
fact. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in these
forward-looking statements as a result of various factors,
including the risk that Alto’s expectations concerning the
appointment of Dr. Radhakrishnan to its Board of Directors may not
be realized, and other important factors, any of which could cause
Alto’s actual results to differ from those contained in the
forward-looking statements, which are described in greater detail
in the section titled “Risk Factors” in Alto’s Final Prospectus
filed with the Securities and Exchange Commission (“SEC”) on
February 5, 2024, pursuant to Rule 424(b)(4) under the Securities
Act of 1933, as amended, as well as in other filings Alto may make
with the SEC in the future. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Alto expressly disclaims any obligation to update any
forward-looking statements contained herein, whether because of any
new information, future events, changed circumstances or otherwise,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311538773/en/
Investor Contact Nick Smith
investors@altoneuroscience.com
Media Contact Jordann Merkert
media@altoneuroscience.com
Grafico Azioni Alto Neuroscience (NYSE:ANRO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Alto Neuroscience (NYSE:ANRO)
Storico
Da Set 2023 a Set 2024